Taking Rapaflo While Pregnant
Rapaflo™ (
silodosin) is a prescription drug approved to treat
enlarged prostate symptoms. Although it appears that Rapaflo probably poses little risk to a pregnant woman or the developing fetus, it should be noted that this medication is not approved for any use in women.
The U.S. Food and Drug Administration (FDA) uses a pregnancy category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category B is given to medicines that have not been adequately studied in pregnant humans but do not appear to cause harm to the fetus in animal studies.
When very large doses of Rapaflo were given to pregnant rats and rabbits, no problems were seen. However, it is important to note that animals do not always respond to medicines the same way that humans do. Therefore, a pregnancy Category B medicine should be given to a pregnant woman only if the healthcare provider believes that the benefits to the pregnant woman outweigh any possible risks to the unborn child.
Again, it should be noted that Rapaflo is approved only for treating an
enlarged prostate and is not approved for any use in women.
If you are pregnant or thinking about becoming pregnant, let your healthcare provider know. He or she will consider both the benefits and risks of Rapaflo during pregnancy before making a recommendation for your particular situation.
